0G8X Stock Overview
A diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Immunovia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.40 |
| 52 Week High | kr3.30 |
| 52 Week Low | kr0.98 |
| Beta | 2.6 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -57.58% |
| 3 Year Change | -98.63% |
| 5 Year Change | n/a |
| Change since IPO | -98.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0G8X | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 0.5% |
| 1Y | -57.6% | -9.7% | 6.3% |
Return vs Industry: 0G8X underperformed the UK Medical Equipment industry which returned -9.8% over the past year.
Return vs Market: 0G8X underperformed the UK Market which returned 6.2% over the past year.
Price Volatility
| 0G8X volatility | |
|---|---|
| 0G8X Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0G8X has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0G8X's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 11 | Jeff Borcherding | www.immunovia.com |
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB (publ) Fundamentals Summary
| 0G8X fundamental statistics | |
|---|---|
| Market cap | kr65.76m |
| Earnings (TTM) | -kr260.73m |
| Revenue (TTM) | kr1.21m |
54.3x
P/S Ratio-0.3x
P/E RatioIs 0G8X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0G8X income statement (TTM) | |
|---|---|
| Revenue | kr1.21m |
| Cost of Revenue | kr5.64m |
| Gross Profit | -kr4.43m |
| Other Expenses | kr256.30m |
| Earnings | -kr260.73m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -5.76 |
| Gross Margin | -365.98% |
| Net Profit Margin | -21,529.89% |
| Debt/Equity Ratio | 0% |
How did 0G8X perform over the long term?
See historical performance and comparison